The most recent recipients of FDA's breakthrough therapy designation (BTD) will see the benefits concentrated in the submission and review stages, because pivotal trials were under way before the coveted expedited review designation was granted.
While breakthrough status earns greater FDA input on development, including clinical trial design, as well as an "all-hands-on-deck" approach to...







